Physician profile
Rachel E Kaczynski
NPI 1487942736
$2,901.66
in general payments reported to CMS, 2019-2025
12 companies · $87.73 in 2025
The $87.73 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2023: $793 · 2024: $1,863 · 2025: $87.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,500 · Food and Beverage: $999 · Entertainment: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,500.00 |
| Food and Beverage | $998.52 |
| Entertainment | $244.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kub Technologies INC. | $1,775.78 | 2023-2024 | Mozart |
| Myriad Genetic Laboratories, INC. | $415.20 | 2023 | Precisetumor |
| Endomagnetics LTD | $206.60 | 2024 | Magtrace, Magseed |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| Immunogen, INC. | $124.99 | 2023 | Elahere |
| Acell, INC. | $33.53 | 2019 | |
| Pharmacosmos Therapeutics INC. | $28.27 | 2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $21.68 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $19.61 | 2025 | |
| Blueprint Medicines Corporation | $18.17 | 2025 | Ayvakit |
| Kerecis Limited | $7.84 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Kaczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.